Morita therapy for obsessive-compulsive disorder: A systematic review and meta-analysis

Australas Psychiatry. 2022 Aug;30(4):436-443. doi: 10.1177/10398562211070151. Epub 2022 Mar 14.

Abstract

Objective: To assess the clinical efficacy of Morita therapy in combination with pharmacotherapy in adults who were diagnosed with current OCDs.

Methods: We searched 10 databases to identify articles written in English or Chinese that were published until 15 April 2021. Randomized controlled trials were included. Two authors of this review independently selected the studies, assessed the risk of bias, and extracted the data.

Results: Twenty-one studies with a total of 1604 participants met the inclusion criteria. Morita therapy plus pharmacotherapy was significantly superior to pharmacotherapy alone in the efficiency of OCD (RR = 1.34, 95% CI: 1.26 to 1.44, I2 = 0%), and better in reducing OCD severity symptoms (MD = -3.55, 95% CI: -4.34 to -2.75, I2 = 80%).

Conclusion: Our meta-analysis and systematic review suggest that Morita therapy may be an effective approach to improve OCDs.

Keywords: Morita therapy; meta-analysis; obsessive-compulsive disorders.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adult
  • Humans
  • Obsessive-Compulsive Disorder* / drug therapy
  • Treatment Outcome